CCCC Key Statistics, Chart & Performance
The current stock price of CCCC is 2.23 USD. In the past month the price increased by 8.78%. In the past year, price decreased by -43.4%.
CCCC Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to CCCC. When comparing the yearly performance of all stocks, CCCC is a bad performer in the overall market: 87.85% of all stocks are doing better.
CCCC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CCCC. The financial health of CCCC is average, but there are quite some concerns on its profitability.
CCCC Financial Highlights
Over the last trailing twelve months CCCC reported a non-GAAP Earnings per Share(EPS) of -1.67. The EPS increased by 2.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.85% | ||
| ROE | -77.12% | ||
| Debt/Equity | 0 |
CCCC Forecast & Estimates
14 analysts have analysed CCCC and the average price target is 11.66 USD. This implies a price increase of 422.74% is expected in the next year compared to the current price of 2.23.
For the next year, analysts expect an EPS growth of -4.99% and a revenue growth -12.79% for CCCC
CCCC Ownership
CCCC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.68 | 378.84B | ||
| AMGN | AMGEN INC | 15.11 | 177.92B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.42 | 111.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.29 | 77.04B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 704.45 | 47.46B | ||
| INSM | INSMED INC | N/A | 34.43B | ||
| NTRA | NATERA INC | N/A | 31.91B | ||
| BIIB | BIOGEN INC | 9.82 | 24.12B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 23.25B | ||
| INCY | INCYTE CORP | 16.54 | 20.85B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.62 | 20.02B |
Related stock screener links
About CCCC
Company Profile
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 110 full-time employees. The company went IPO on 2020-10-02. The firm is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The firm is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. The company is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
Company Info
C4 THERAPEUTICS INC
490 Arsenal Way, Suite 120
Watertown MASSACHUSETTS 02472 US
CEO: Andrew J. Hirsch
Employees: 110
Phone: 16172310700
C4 THERAPEUTICS INC / CCCC FAQ
What does CCCC do?
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. The company is headquartered in Watertown, Massachusetts and currently employs 110 full-time employees. The company went IPO on 2020-10-02. The firm is focused on delivering targeted protein degradation science to create a new generation of medicines that transform patients’ lives. The firm is focused on progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. Its advanced product candidate, cemsidomide, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3. Cemsidomide is in clinical development for multiple myeloma (MM), and non-Hodgkin lymphoma (NHL). Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. The company is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective BiDAC degrader of epidermal growth factor receptor (EGFR), with an L858R mutation in non-small lung cancer (NSCLC).
What is the stock price of C4 THERAPEUTICS INC today?
The current stock price of CCCC is 2.23 USD. The price increased by 0.45% in the last trading session.
What is the dividend status of C4 THERAPEUTICS INC?
CCCC does not pay a dividend.
What is the ChartMill technical and fundamental rating of CCCC stock?
CCCC has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Is C4 THERAPEUTICS INC (CCCC) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CCCC.
What is the market capitalization of CCCC stock?
C4 THERAPEUTICS INC (CCCC) has a market capitalization of 216.11M USD. This makes CCCC a Micro Cap stock.
What is the Short Interest ratio of C4 THERAPEUTICS INC (CCCC) stock?
The outstanding short interest for C4 THERAPEUTICS INC (CCCC) is 8.49% of its float.